The American Enterprise Institute (AEI), a public policy think tank, published a piece this week by Kirsten Axelsen on the potential cost effects of the Inflation Reduction Act, including discouraging generic entry and the lack of a clear role for assessing value for the price. The post is based on a panelist discussion she hosted with AEI last month.
“The Inflation Reduction Act (IRA) will affect the cost of medicines in Medicare. Since making drugs less expensive is an objective of the law, I spoke with two experts in drug costs about it: AEI’s Amitabh Chandra and Craig Burton of the Association for Accessible Medicines. We concentrated on how the IRA will affect the availability and cost of generics and biosimilars, drug prices, and patient out-of-pocket costs more broadly.”
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-03-19-17-30-27-593-65f9cbb3bf22b75d160b136f.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-04-25-12-46-49-709-662a50b99766bc4f3d58967f.jpg)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-04-22-08-46-05-640-662623cd0532c9880e85e938.jpg)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-04-18-09-16-42-370-6620e4fa7330266071d4ac1d.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Document/2024-04-15-09-40-05-618-LS_marzec_2024_EN_thumbnail_1.png)
